Indian State Authorities Report 27 Drugs from Leading Firms Failed Quality Tests

Indian drug regulators in seven states have accused 18 drugmakers of selling substandard therapies after quality tests identified a range of product issues ranging from deceptive labeling to inappropriate quantities of active ingredients.

The drugmakers drawing scrutiny from the state authorities include Abbott India, GSK India, Sun Pharma, Cipla, Wockhardt Pharma and Glenmark Pharma.  Twenty-seven products failed to meet quality standards.

The drug regulators cited GSK India misbranding Phexin, an antibiotic for respiratory infections, by listing cephalexin as the drug’s primary ingredient.